Atovaquone-Proguanil: A Promising Therapy for Persistent Relapsing Babesiosis [PDF]
Case Reports in Infectious DiseasesWe report a challenging case of persistent relapsing babesiosis in an immunocompromised host that was successfully managed with atovaquone-proguanil (Malarone).
Mahum Shahid +3 more
doaj +4 more sources
Tolerability of Atovaquone—Proguanil Application in Common Buzzard Nestlings [PDF]
Veterinary Sciences, 2022 Differences in drug tolerability among vertebrate groups and species can create substantial challenges for wildlife and ex situ conservation programmes.
Anja Wiegmann +8 more
doaj +2 more sources
Late clinical failure associated with cytochrome b codon 268 mutation during treatment of falciparum malaria with atovaquone–proguanil in traveller returning from Congo [PDF]
Malaria Journal, 2020 Background The drug combination atovaquone–proguanil, is recommended for treatment of uncomplicated falciparum malaria in France. Despite high efficacy, atovaquone–proguanil treatment failures have been reported.
Laurencie Massamba +12 more
doaj +2 more sources
A survey on outcomes of accidental atovaquone–proguanil exposure in pregnancy [PDF]
Malaria Journal, 2018 Background Malaria chemoprophylaxis options in pregnancy are limited, and atovaquone–proguanil (AP) is not recommended because of insufficient safety evidence.
Kathrine R. Tan +3 more
doaj +2 more sources
Safety of atovaquone-proguanil during pregnancy. [PDF]
J Travel Med, 2019 Malaria during pregnancy increases the risk of maternal and foetal complications. There are very limited options for prophylaxis in pregnant travellers. Atovaquone-Proguanil (AP or Malarone®) is an effective and well-tolerated antimalarial medication, but is not recommended for use in pregnancy due to limited data on safety.
Mayer RC, Tan KR, Gutman JR.
europepmc +4 more sources
Complete attenuation of Plasmodium falciparum sporozoites by atovaquone–proguanil [PDF]
EMBO Molecular MedicineTo develop a Plasmodium falciparum (Pf) vaccine that precludes replication inside the host for improved vaccine safety, we tested chemo-attenuation (CVac) of sporozoites (SPZ) with atovaquone–proguanil (AP). In mice, P.
Steffen Borrmann +39 more
doaj +2 more sources
Atovaquone-proguanil and reduced digestive cancer risk: a Toxoplasma gondii connection [PDF]
Gut MicrobesEmerging evidence suggests microbial pathogens contribute to digestive cancer risk. Atovaquone – proguanil (A-P), an antimalarial with antiparasitic activity, has been associated with a reduced risk of colorectal cancer (CRC).
Ariel Israel +6 more
doaj +2 more sources
Splenic accumulation of intact Plasmodium ovale sensu lato-infected red blood cells in a patient presenting with splenic rupture. [PDF]
PLoS Neglected Tropical DiseasesA 35-year-old man had splenic rupture just after starting antimalarial treatment with atovaquone-proguanil followed by artesunate for acute Plasmodium ovale sensu lato infection. Spleen histology showed a 10-fold accumulation of intact P.
Ghania Benabdelmoumen +11 more
doaj +2 more sources
Congenital babesiosis in China: first molecularly confirmed case of vertical transmission of Babesia microti [PDF]
Emerging Microbes and InfectionsCongenital babesiosis is rarely reported globally. We report a 74-day-old male infant presented with fever, pallor, and severe, life-threatening haemolytic anaemia (haemoglobin: 45 g/L).
Junwen Liu +10 more
doaj +2 more sources
Delayed Onset of Symptoms and Atovaquone-Proguanil Chemoprophylaxis Breakthrough by Plasmodium malariae in the Absence of Mutation at Codon 268 of pmcytb. [PDF]
PLoS Neglected Tropical Diseases, 2015 Plasmodium malariae is widely distributed across the tropics, causing symptomatic malaria in humans with a 72-hour fever periodicity, and may present after latency periods lasting up to many decades.
Beatrix Huei-Yi Teo +9 more
doaj +2 more sources